FDA Approves Nivolumab With Chemotherapy for Gastric and Esophageal Cancer

The FDA has granted approval to nivolumab (Opdivo®, Bristol-Myers Squibb Company) in combination with fluoropyrimidine- and platinum-containing chemotherapy for the initial treatment of patients with advanced/metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma. "Standard first-line chemotherapy options for advanced or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric cancer/gastroesophageal junction cancer result in poor overall su...
Continue reading

Advanced Esophageal Cancer: High Risk of Venous Thromboembolic Events During Preoperative Therapy

An exploratory analysis of data from a phase 3 trial observed a high incidence of venous thromboembolic events (VTEs) in patients with locally advanced resectable esophageal cancer undergoing preoperative chemotherapy and chemoradiotherapy, especially in patients with adenocarcinoma. The occurrence of VTEs, including deep vein thrombosis and pulmonary embolus, can negatively impact the clinical outcomes of patients receiving cancer treatment, reducing quality of life and increasing the risk of m...
Continue reading

New Therapeutic Targets Found in Esophageal Cancer

​Esophageal adenocarcinoma (EAC), the most common type of esophageal cancer, is highly deadly, with only 20% of patients surviving five years from diagnosis. It is resistant to standard chemoradiotherapy treatments and has few targeted therapies. "Targeted therapies are virtually non-existent," remarked Kishore Guda, DVM, PhD, Associate Professor in the Case Comprehensive Cancer Center of Case Western Reserve University. "Treatment advancements are also slowed because we don't know exactly what ...
Continue reading

Genetic Factor Found in Esophageal Cancer’s Racial Disparity

Why is esophageal adenocarcinoma (EAC) significantly more common among European Americans than among African Americans, even though both groups experience similar rates of gastroesophageal reflux disease (GERD), a relative risk factor for this condition? Researchers have found the reason, along with a potential means to end this disparity. "We've known for a long time that esophageal adenocarcinoma primarily affects Caucasians and very rarely affects African Americans," stated David G. Beer, PhD...
Continue reading

Subscribe

Get the latest updates delivered to your inbox!

Follow Us

Copyright © 2021 Oncology Data Advisor. All rights reserved.